Kamari Pharma Announces New Data Presented at the 81st Annual Meeting of the Society for Investigative Dermatology

Posted: May 18, 2024 at 2:42 am

Phase 1b clinical trial of KM-001 demonstrated favorable safety profile and high responder rate of 87% in patients with palmoplantar keratoderma and pachyonychia congenita

Continue reading here:
Kamari Pharma Announces New Data Presented at the 81st Annual Meeting of the Society for Investigative Dermatology

Related Posts